Navigation Links
Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Date:2/11/2008

nitiate clinical trials for its first two FOBs in 2008, both of whose brand sales represent over $3 billion in current sales world wide. Members of Insmed's skilled biologics team have worked on over 50 therapeutic proteins. Their focused protein-based drug development backgrounds, coupled with the Company's FDA-approved protein manufacturing facility, and clinical and regulatory expertise, positions Insmed, upon the establishment of a regulatory pathway, to be an initial entrant into the U.S. FOBs market with a broad range of medicines following the expiration of patents covering the innovator products.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. Insmed has a state-of-the- art, FDA-approved biologic commercial manufacturing facility in Boulder, Colorado and a Corporate office in Richmond, Virginia. For more information, please visit http://www.insmed.com.

About Robert J. Shapiro

Robert J. Shapiro is the chairman of Sonecon, LLC, a private firm that advises U.S. and foreign businesses, governments and non-profit organizations. Dr. Shapiro has advised, among others, U.S. President Bill Clinton and British Prime Minister Tony Blair; private firms including Amgen, AT&T, Gilead Sciences, Google, MCI, Inc., SLM Corporation, Nordstjernan of Sweden, and Fujitsu of Japan; and non-profit organizations including the American Public Transportation Association, the Education Finance Council, BIO, and the U.S. Chamber of Commerce. He is also chairman of the Globalization Initiative of NDN, co-chair of the American Task Force Argentina, Policy Fellow of the Georgetown University School of Business, Senior Fellow of the Progressive Policy Institute (PPI), and a director of the Ax:son-Johnson Foundation in Sweden. From 1997 to 2001, Dr. Shapir
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, Inc. ... treatments for urological and related conditions, announced today that ... private placement convertible note financing, raising a total of ... totaling $3.175 million. Josh Disbrow ... this private placement are intended to be used to ...
(Date:9/2/2015)... Virginia , September 2, 2015 ... der Gewinner des Wettbewerbs BeHEARD von 2015 bekanntgeben ... internationalen vom Rare Genomics Institute. Biovista ... von Medikamenten für die Behandlung anderer Krankheiten als ... Steven Laffoon und sein Team bei ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... equipment, to creating professional commercial video content, to analysis of athletic performance. Producing ... events that go by too quickly to process with the naked eye. ...
(Date:9/1/2015)... CHICAGO , Sept. 1, 2015 The ... of Intent (LOI) for its Discovery Research Grant program. ... 2015 at 12:00 noon CDT. Discovery ... projects with the potential to change current diagnostic or ... These grants specifically encourage novel research at its earliest ...
Breaking Biology Technology:Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2
... assessment to be added to the, ... 28 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or "Company") ... on activities as well as an interim progress ... is conducting a human Phase 1b/2a clinical trial ...
... Sigma-Aldrich (Nasdaq: SIAL ) today announced the global ... provides a novel and powerful approach to RNAi screening in ... http://www.sigma.com/esirna ) incorporates a pool of hundreds of ... designed to eliminate the trial and error approach of identifying ...
... Techne Corporation,s (Nasdaq: TECH ) consolidated net ... to $27.6 million or $.74 per diluted share compared with ... ended March 31, 2008. For the nine months ended ... $79.9 million or $2.10 per diluted share compared with $76.3 ...
Cached Biology Technology:Resverlogix Provides Quarterly Update 2Resverlogix Provides Quarterly Update 3Resverlogix Provides Quarterly Update 4Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 2Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 3Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 2Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 3Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 5Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 6Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 7
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... can induce a group of aggressive immune cells that ... is the result of a study conducted by Dr. ... Haven and the Broad Institute of the Massachusetts Institute ... Ralf Linker (Dept. of Neurology, University Hospital Erlangen), Professor ...
... today concludes that nearly half of Africa,s wild lion populations ... without urgent conservation measures. The plight of many lion populations ... - and fencing humans out - may be their only ... Minnesota,s Professor Craig Packer and co-authored by a large team ...
... University of Massachusetts Amherst including assistant professor Peter Chien ... degradation help to regulate the delicate ballet of cell ... each other in "mutually assured cleanup" to insure that ... dispose of leftover proteins with the aid of proteases ...
Cached Biology News:International study: Excess dietary salt may drive the development of autoimmune diseases 2International study: Excess dietary salt may drive the development of autoimmune diseases 3New report confirms almost half of Africa's lions facing extinction 2New insight into double-protected dance of cell division 2
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
... Anti-phospho-Hck [pTyr 209/ pSer 211 ] affinity ... in Dulbecco's phosphate buffered saline (without Mg 2+ ... 1.0 mg/ml BSA (IgG and protease free) and ... from the region of mouse Hck that contains ...
... Useful as a positive control for ... to chromatin in vivo is a crucial ... extent of crosslinking is probably the most ... subsequent immunoprecipitation step should be taken into ...
Biology Products: